Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
Mikhail N KosiborodMark C PetrieBarry A BorlaugJaved ButlerMelanie J DaviesG Kees HovinghDalane W KitzmanDaniél V MøllerMarianne B TreppendahlSubodh VermaThomas J JensenKaroline LiisbergMarie L LindegaardWalter AbhayaratnaFozia Z AhmedTuvia Ben-GalVijay ChopraJustin A EzekowitzMichael FuHiroshi ItoMałgorzata LelonekVojtěch MelenovskýBela MerkelyJulio NunezEduardo Roque PernaMorten SchouMichele SenniKavita SharmaPeter van der MeerDirk Von LewinskiDennis WolfSanjiv J Shahnull nullPublished in: The New England journal of medicine (2024)
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrials.gov number, NCT04916470.).
Keyphrases
- type diabetes
- weight loss
- heart failure
- insulin resistance
- glycemic control
- metabolic syndrome
- bariatric surgery
- cardiovascular disease
- physical activity
- weight gain
- mental health
- randomized controlled trial
- clinical trial
- skeletal muscle
- sleep quality
- depressive symptoms
- drug induced
- obese patients
- open label
- placebo controlled